These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 17459266)

  • 1. Testosterone replacement therapy and prostate cancer: a word of caution.
    Brand TC; Canby-Hagino E; Thompson IM
    Curr Urol Rep; 2007 May; 8(3):185-9. PubMed ID: 17459266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].
    Rinnab L; Gust K; Hautmann RE; Küfer R
    Urologe A; 2009 May; 48(5):516-22. PubMed ID: 19296069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer in Klinefelter syndrome during hormonal replacement therapy.
    Hwang JJ; Dharmawardana PG; Uchio EM; Wynberg J; Phillips JL
    Urology; 2003 Nov; 62(5):941. PubMed ID: 14624928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of testosterone replacement therapy following radical prostatectomy.
    Khera M; Lipshultz LI
    Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    Barqawi A; Crawford ED
    Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Testosterone and the prostate].
    Sperling H; Rossi R; Lümmen G; Rübben H
    Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of testosterone-replacement therapy and recommendations for monitoring.
    Rhoden EL; Morgentaler A
    N Engl J Med; 2004 Jan; 350(5):482-92. PubMed ID: 14749457
    [No Abstract]   [Full Text] [Related]  

  • 12. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.
    Curran MJ; Bihrle W
    Urology; 1999 Feb; 53(2):423-4. PubMed ID: 9933071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone and the aging male: to treat or not to treat?
    Bain J
    Maturitas; 2010 May; 66(1):16-22. PubMed ID: 20153946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
    Jensen CF; Fode M; Østergren P; Sønksen J
    Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Testosterone substitution with special regard to prostate cancer].
    Beintker M; Behre H
    Urologe A; 2008 Dec; 47(12):1588-91. PubMed ID: 18931991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
    Kaplan AL; Hu JC
    Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of androgen therapy in men with prostate cancer.
    Rajan P; Tharakan T; Chen R
    Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.
    Shabsigh R; Crawford ED; Nehra A; Slawin KM
    Int J Impot Res; 2009; 21(1):9-23. PubMed ID: 18633357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Risk and Monitoring During Testosterone Replacement Therapy.
    Bhasin S; Thompson IM
    J Clin Endocrinol Metab; 2024 Jul; 109(8):1975-1983. PubMed ID: 38753865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.